Chih-Cheng Hsieh1,2, Han-Shui Hsu1,3, Anna Fen-Yau Li4,5, Yann-Jang Chen2,6,7. 1. Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei. 2. Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei. 3. Institute of Emergency and Critical Care Medicine, School of Medicine, National Yang-Ming University, Taipei. 4. Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei. 5. School of Medicine, National Yang-Ming University, Taipei. 6. Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University, Taipei. 7. Department of Pediatrics, Renai Branch, Taipei City Hospital, Taipei.
Abstract
BACKGROUND: Even with the advance of diagnosis and the treatment, the 5-year survival rate for esophageal cancer patients is still poor. The checkpoint protein inhibition provides another choice to improve the survival. The expression of the programmed death ligand-1 (PD-L1) was reported but the clinical relevance remained inconsistent in esophageal cancer. Besides, there were few references about the other ligand, programed death ligand-2 (PD-L2). In this study, we evaluated the expressions of PD-L1 and PD-L2 in patients with esophageal squamous cell carcinoma (ESCC) and assessed their clinical relevance. METHODS: From 1996 to 2011, 150 patients undergone complete surgical resection for ESCC were enrolled. Clinical data were recorded. Expression of PD-L1 and PD-L2 on cytoplasm in paraffin embedded tumor samples were analyzed by immunohistochemistry staining and scored with a semi-quantitative method. RESULTS: Of the patients, 96 (64.0%) patients had PD-L1 overexpression and 63 (42.0%) had PD-L2 overexpression. There was a correlation between the expression of PD-L1 and PD-L2 (P<0.001). Patients without overexpression of PD-L1, pathological T1-2 and N0 status, pathological stage I-II and no post-operative adjuvant treatment had a better disease free survival (DFS). In multivariate analysis, PD-L1 expression and pathological stage were the independent prognostic factors for DFS. The expression of PD-L2 did not influence the DFS. Although not statistically significant, patients without overexpression of PD-L1 and PD-L2 seem to have a better overall survival (OS). CONCLUSIONS: The overexpression of PD-L1 on cytoplasm, not PD-L2, is an independent prognostic factor for DFS in patients with ESCC undergone esophagectomy. However, there is a trend which suggested that patients without overexpression of PD-L1 and PD-L2 had a better OS.
BACKGROUND: Even with the advance of diagnosis and the treatment, the 5-year survival rate for esophageal cancer patients is still poor. The checkpoint protein inhibition provides another choice to improve the survival. The expression of the programmed death ligand-1 (PD-L1) was reported but the clinical relevance remained inconsistent in esophageal cancer. Besides, there were few references about the other ligand, programed death ligand-2 (PD-L2). In this study, we evaluated the expressions of PD-L1 and PD-L2 in patients with esophageal squamous cell carcinoma (ESCC) and assessed their clinical relevance. METHODS: From 1996 to 2011, 150 patients undergone complete surgical resection for ESCC were enrolled. Clinical data were recorded. Expression of PD-L1 and PD-L2 on cytoplasm in paraffin embedded tumor samples were analyzed by immunohistochemistry staining and scored with a semi-quantitative method. RESULTS: Of the patients, 96 (64.0%) patients had PD-L1 overexpression and 63 (42.0%) had PD-L2 overexpression. There was a correlation between the expression of PD-L1 and PD-L2 (P<0.001). Patients without overexpression of PD-L1, pathological T1-2 and N0 status, pathological stage I-II and no post-operative adjuvant treatment had a better disease free survival (DFS). In multivariate analysis, PD-L1 expression and pathological stage were the independent prognostic factors for DFS. The expression of PD-L2 did not influence the DFS. Although not statistically significant, patients without overexpression of PD-L1 and PD-L2 seem to have a better overall survival (OS). CONCLUSIONS: The overexpression of PD-L1 on cytoplasm, not PD-L2, is an independent prognostic factor for DFS in patients with ESCC undergone esophagectomy. However, there is a trend which suggested that patients without overexpression of PD-L1 and PD-L2 had a better OS.
Entities:
Keywords:
Programmed death ligand-1 (PD-L1); cytoplasm; esophageal squamous cell carcinoma (ESCC); overexpression; programed death ligand-2 (PD-L2); survival
Authors: Rajeev Dhupar; Lauren Van Der Kraak; Arjun Pennathur; Matthew J Schuchert; Katie S Nason; James D Luketich; Michael T Lotze Journal: Ann Thorac Surg Date: 2017-04 Impact factor: 4.330
Authors: Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Xingluo Liu; Jian Xin Gao; Jing Wen; Lijie Yin; Ou Li; Tao Zuo; Thomas F Gajewski; Yang-Xin Fu; Pan Zheng; Yang Liu Journal: J Exp Med Date: 2003-06-16 Impact factor: 14.307
Authors: Samantha M Y Chen; Alexandra L Krinsky; Rachel A Woolaver; Xiaoguang Wang; Zhangguo Chen; Jing H Wang Journal: Mol Carcinog Date: 2020-02-03 Impact factor: 4.784